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ABSTRACT 
Chiral micellar electrokinetic chromatography with laser induced fluorescence detection 
(chiral-MEKC-LIF) was used to investigate D- and L-amino acids contents in 
cerebrospinal fluid (CSF) samples related to different Alzheimer disease (AD) stages. 
CSF samples were taken from i) control subjects (S1 pool), ii) subjects showing a mild 
cognitive impairment (MCI) who remained stable (S2 pool), iii) subjects showing a 
MCI that progressed to AD (S3 pool) and iv) subjects diagnosed with AD (S4 pool). 
The optimized procedure only needed 10 µL of CSF and it included sample cleaning, 
derivatization with FITC and chiral-MEKC-LIF separation. Eighteen standard amino 
acids were baseline separated with efficiencies up to 703000 plates/m, high sensitivity 
(LODs in the nM range) and good resolution (values ranging from 2.6 to 9.5). Using 
this method, L-Arg, L-Leu, L-Gln, GABA, L-Ser, D-Ser, L-Ala, Gly, L-Lys, L-Glu and 
L-Asp were detected in all the CSF samples. S3 and S4 samples (i.e., AD subjects) 
showed significant lower amounts of L-Arg L-Lys, L-Glu and L-Asp compared to the 
non-Alzheimer S1 and S2 samples, showing the S4 group the lowest amounts of L-Arg 
L-Lys, L-Glu and L-Asp. Moreover, GABA was significantly higher in AD subjects 
with the highest amount also found for S4. No significant differences were observed for 
the rest of amino acids including D-Ser. Based on the obtained chiral-MEKC-LIF data, 
it was possible to correctly classify all the samples into the four groups. These results 
demonstrate that the use of enantioselective procedures as the one developed in this 
work can provide some new light on the investigations of AD, including the discovery 
of new biomarkers related to different stages of AD. 
 
INTRODUCTION 
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Amino acids have focused much attention in biomedical research, medical diagnostics, 
clinical chemistry, and the pharmaceutical industry, because they play essential roles in 
control and regulation of crucial functions in the human body [1,2]. Moreover, it has 
recently been found that L- and D-amino acids can play different biological functions 
and, therefore, analysis of these chiral forms in biological fluids may provide a means 
of diagnosis and possible treatment of diseases [3-5]. However, the knowledge of D-
amino acids in biological samples is still limited and most of the D-amino acids are not 
well investigated yet, concluding that more work is needed in this area of research [5]. 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder with an estimated worldwide 
prevalence of over eighteen million people, and is predicted to increase with an 
increasing elderly population [6]. AD is characterized by cognitive deficits and memory 
impairment, and there is currently no cure for this disease. Biochemical processes 
accounting for neurodegeneration are not known but are likely to include the 
metabolism of amino acids [6]. Since free amino acids are important in 
neurotransmission, receptor function and are implicated in neurotoxicity, changes in 
free amino acids metabolism can be an early indicator of neurodegeneration in AD. This 
early diagnose is considered crucial for a potential AD cure because treatment might be 
most effective when initiated very early in the course of AD, before amyloid plaques 
and neurodegeneration become too widespread. Thus, biomarkers are needed that can 
detect AD in the predementia phase or, ideally, in presymptomatic individuals [7,8]. 
Moreover, in vitro assays have recently shown that aggregation and folding parameters 
of amyloid beta are stereospecific and the aggregation property strongly depends upon 
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the amino acid sequence and their stereospecificity [9], suggesting the stereospecific 
role of amino acids comprising aggregation and its relevance to neurodegeneration.  
 
Analysis of chiral amino acids can, therefore, be an interesting strategy to further 
investigate AD. Moreover, analysis of the chiral forms of amino acids can provide more 
light to the contradictory results usually found in the literature on amino acids analysis 
related to AD. For instance, some researchers have found no differences in glutamate 
levels in the hippocampus and cerebral cortices between normal and AD patients [10], 
whereas other researchers have shown that this amino acid was elevated [11] or reduced 
[12,13] in brain of AD patients. Similarly, aspartate levels have been found increased 
[14], reduced [12,13] or virtually unaltered in AD compared to normal brain [11]. The 
same differing results are found comparing the published works dealing with the 
analysis of amino acids in cerebrospinal fluid (CSF) from AD and control subjects using 
chromatographic [6,15-19] or electrodriven separation techniques [6,20-23]. Though 
further studies are needed to clarify whether the alterations in amino acids in an AD 
brain and CSF is a factor or a result, the elucidation of the relationship of amino acids 
(including their L- and D-forms) and AD might offer new insights to overcome this 
devastating disease.  
 
In this regard, chiral capillary electrophoresis (CE) can be a good choice to carry out the 
analysis of D- and L- amino acids from CSF samples based on CE high separation 
efficiency, enormous resolving power, large peak capacities, short analysis times and 
small sample and reagents volume (including tiny amounts of chiral selectors) [24]. 
Although, as mentioned above, some previous works have already shown the content of 
amino acids in CSF using different techniques such as HPLC [6,15-17] or CE [6,20,22], 
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to our knowledge, only two papers have faced the complex issue regarding the analysis 
of chiral amino acids in CSF samples related to AD. Namely, Fisher et al. showed in a 
first work using HPLC that free D-Asp was significantly higher (p < 0.01) in AD 
ventricular CSF compared to normal ventricular CSF [25]. However, in a posterior 
work, they found that also D-Ser was significantly higher (p < 0.01) in AD ventricular 
CSF [26]. They concluded that CSF could reflect the degenerative process that occurs in 
AD since CSF is the repository of amino acids from the brain, although, they state that 
more work is needed to corroborate this crucial point [26].  
 
The goal of this work is, therefore, to carry out the profiling of the main D- and L-
amino acids that can be found in CSF samples related to different stages of AD. To do 
this, a new analytical CE method is developed combining micellar electrokinetic 
chromatography (MEKC) with a chiral selector and laser induced fluorescence (LIF) 
detection to analyze a group of 18 selected L- and D-amino acids that can be found in 
CSF. The developed chiral-MEKC-LIF method is fast and reproducible and allows the 
separation of the 18 amino acids with good efficiency and sensitivity.  
 
MATERIALS AND METHODS  
 
Chemicals 
 
All chemicals were of analytical reagent grade and used as received. -CD was used as 
chiral selector for the MEKC running buffer together with sodium dodecyl sulfate 
(SDS) and boric acid, all from Sigma-Aldrich (St. Louis, MO, USA). Water was 
deionized by using a Milli-Q system from Millipore (Bedford, MA, USA). An aqueous 
solution containing 5 mol/L of sodium hydroxide from Panreac Quimica S.A. 
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(Barcelona, Spain) was used to adjust the pH of the BGEs. A 0.1 mol/L NaOH solution 
was used to rinse the capillary. BGEs were stored at 4°C and warmed at room 
temperature before use. All solutions were filtrated through a 0.45 µm membrane filter. 
A 20 mM fluorescein isothiocyanate (FITC) solution from Sigma-Aldrich was prepared 
in acetone from Merck (Darmstadt, Germany). Standard L- and D-amino acids were 
from Sigma-Aldrich. Stock solutions of 0.05 mM Gly, 0.10 mM D\L Arg, D\L Ser, D\L 
Leu, D\L Ala, D\L Gln, D\L Glu, GABA and 0.50 mM D\L Lys and D\L Asp were 
prepared in Milli-Q water. The stock solutions were stored at 4°C.  
 
CSF samples 
 
Study population 
The patients included in the study (n=99) were from the Memory Clinic at the 
Karolinska University Hospital in Huddinge (Sweden). 33 had just subjective cognitive 
impairment (SCI) and they were considered as control group (sample 1, S1), 39 had 
mild cognitive impairment (MCI) of which 26 remaining stable (sample 2, S2) and 13 
had progression-to-Alzheimer disease within two years time (sample 3, S3), the four 
group was composed of 27 patients already presenting mild Alzheimer disease (sample 
4, S4). These patients were all living independently in the community. They were 
evaluated according to a standard comprehensive assessment protocol including clinical 
examination, brain imaging, electroencephalography, analyses of blood and CSF 
(including total tau (T-Tau), phospho-tau (P-Tau), and A1-42) and a detailed 
neuropsychological evaluation. Dementia and AD were diagnosed according to DSM-
IV and NINCDS-ADRDA criteria. MCI patients from S2 were not demented, had (self 
and/or an informant) reported cognitive decline and impairment on objective cognitive 
 7 
tasks, and S3 had preserved basic AD/minimal impairment in complex instrumental 
functions. S1 patients had cognitive complaints without impairment on objective 
cognitive tasks. Patients with psychiatric disorders (i.e. depression, alcohol abuse) or 
other conditions (i.e. diabetes, brain tumours, normal pressure hydrocephalus) were not 
included. The study was conducted under the guidelines of the Declaration of Helsinki 
and approved by the ethics committee of the Karolinska Institutet. 
 
CSF extraction 
CSF samples were obtained by lumbar puncture performed in the sitting position. CSF 
extraction is routinely performed at the Karolinska University Hospital Memory clinic 
in Huddinge (Sweden) as part of the medical examination. The extractions were 
performed in the mornings in fasting patients. CSF samples were obtained from L3/L4 
or L4/L5 interspaces after local anaesthetic infiltration in the skin. After disposal of the 
first mL the following 10 mL were collected in polypropylene tubes. No sample 
contained more than 500 erythrocytes/μL CSF samples was used. Samples were gently 
mixed to avoid gradient effects and centrifuged at 2000×g for 10 min to eliminate cells 
and insoluble material.  Supernatants were immediately aliquoted, immediately frozen 
and stored at -80°C for pending biochemical analyses. In this study, pools of each of the 
4 groups were used. Pools were obtained by mixing 10 µL of each individual sample, 
vortex and immediately stored at -80°C. 
 
Ultrafiltration  
100 l of each sample (S1, S2, S3 and S4) was centrifuged at 14000×g for 25 min on a 
3 kDa membrane to remove proteins from CSF samples. The <3 kDa fraction was used 
for subsequent FITC derivatization procedure. 
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Derivatization procedure 
 
The FITC derivatization procedure was optimized as described below. The selected 
conditions consisted of mixing 10 µL of the standard solution of amino acids or CSF 
sample with 80 µL of a 25 mM sodium borate buffer at pH 10.0 and 10 µL of a 20 mM  
FITC solution (freshly prepared just before derivatization). The reaction took place 
overnight in darkness at room temperature. After derivatization, the solution was stored 
in dark at 4°C before chiral-MEKC-LIF analysis.  
 
MEKC-LIF conditions  
 
All analyses were carried out in triplicate using a P/ACE 2100 CE apparatus from 
Beckman Instruments (Fullerton, CA, USA) equipped with an Ar+ laser at 488 nm 
(excitation wavelength) and 520 nm (emission wavelength), also from Beckman 
Instruments. Bare fused-silica capillary was purchased from Composite Metal Services 
(Worcester, England). The capillary dimensions were 50 cm of detection length, 57 cm 
of total length, and 50-µm i.d. and was thermostated at 30 °C. Injections were made at 
the anodic end using N2 at 0.5 psi (3.45 kPa) for 3 s (hydrodynamic injection of 3.5 nL), 
and the applied voltage was +20 kV. The P/ACE 2100 CE instrument was controlled by 
a PC running the System GOLD software from Beckman. Before first use, new 
capillaries were preconditioned by rinsing with 0.1 M NaOH for 30 min. The washing 
protocol between runs was optimized to obtain adequate repeatability, selecting the 
following conditions: at the beginning of each run, the capillary was rinsed with 0.1 M 
NaOH for 2 min, followed by 2 min with Milli-Q water, and then equilibrated for 5 min 
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with the running buffer. After optimization, 100 mM sodium tetraborate, 80 mM SDS, 
and 20 mM -CD at pH 10.0, was used as running buffer. In order to skip any 
irreproducibility problem derived from buffer depletion, the buffer vial was changed 
every three injections. At the end of the day, the capillary was rinsed with Milli-Q water 
for 10 min, and then nitrogen was passed for 2 min. 
 
Data analysis 
 
Statistical analysis was performed using Statistica 7.1 software (StatSoft Inc.2005, 
USA, www.statsoft.com). First, one-way analysis of variance (ANOVA) of the amino 
acid corrected peak areas (i.e., peak area/migration time) was carried out to detect 
significant differences among the four groups of samples, using a 1% significance level 
and a Scheffe test for means comparison. Then a forward stepwise discriminant analysis 
(FSDA) of the corrected peak areas was applied to select the variables most useful to 
differentiate the four groups of samples and to obtain the classification functions. 
Finally, a Fisher’s canonical variable analysis (Root 1 and Root 2) was performed in 
order to obtain a low-dimensional graphical representation of the samples separating as 
much as possible the groups under study.  
 
RESULTS AND DISCUSSION 
 
A group of eight chiral amino acids (D\L Arg, D\L Ser, D\L Leu, D\L Ala, D\L Gln, 
D\L Glu, D\L Lys and D\L Asp) plus the nonchiral amino acids Gly and GABA was 
initially selected to carry out this study. This selection was based on a literature search 
on the main amino acids usually found in CSF samples. 
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Development of the FITC derivatization procedure  
 
Previous to the optimization of the chiral-MEKC-LIF method, the derivatization 
procedure was studied in order to achieve the maximum amino acid signal with the 
lowest number of interferences from the derivatizing reagent FITC, which is known to 
produce a high number of interfering fluorescent compounds [27]. Besides, different 
parameters were tested in order to obtain a sensitive and robust derivatizing procedure 
of the tiny volume of CSF sample used in this work (10 µL). Different concentrations of 
FITC solution were tested (i.e., to give a final concentration equal to 5, 10 and 20 times 
greater than the concentration of amino acids), different pHs (from 9 to 11) and 
concentrations of sodium tetraborate buffer (from 20 mM to 400 mM) were tested. 
Optimum results in terms of sensitivity and reproducibility of the derivatization method 
of the 10 µL sample were obtained using a FITC solution with a concentration 10 times 
greater than the solution of amino acids, and in a 25 mM sodium tetraborate buffer at 
pH 10.0.  
 
Optimization of chiral-MEKC-LIF separation conditions and figures of merit  
 
Chiral-MEKC-LIF method was optimized using -CD as chiral selector at different 
concentrations (10, 15, and 20 mM) and testing different SDS concentrations (40, 60, 
80, and 100 mM), pH buffer values (9.5, 9.7, 10.0, 10.3) and sodium tetraborate 
concentrations (25, 50, 100, 120 mM). Optimum chiral resolution was obtained for the 
18 amino acids investigated in this work using 100 mM sodium tetraborate, 80 mM 
SDS and 20 mM -CD solution at pH 10.0 as BGE. 
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A typical electropherogram of the amino acids mixture obtained under these conditions 
is shown in Figure 1. As can be seen, using this BGE it is possible to achieve the 
complete chiral-MEKC-LIF separation of D- and L-Arg, D- and L-Leu, D- and L-Gln, 
GABA, D- and L-Ser, D- and L-Ala, Gly, D- and L-Glu, D- and L-Lys, as well as D- 
and L-Asp with resolutions higher than 2.6 in all the cases (see Table 1). Thus, these 
new analytical conditions bring about the baseline separation for the 18 amino acids as 
clearly shown in Figure 1, besides, they are also well separated from the impurities 
coming from the FITC derivatization (peaks marked with an asterisk). Moreover, 
efficiencies ranging from 242000 plates/m for L-Asp to 703000 plates/m for D-Arg 
were achieved corroborating the usefulness of this procedure. Also, the limits of 
detection (LOD), calculated considering a signal to noise ratio equal to three, ranged 
from 0.8 nM for Gly to 16.5 nM for L-Asp, providing limits of quantitation (LOQ) 
ranging from 2.6 nM for Gly to 53.6 nM for L-Asp. The method was determined to be 
reproducible according to the results given in Table 2. Thus, %RSD values obtained for 
intra-day repeatability (five consecutive injections in the same day) were better than 
5.3% and 0.5% for peak areas and migration time, respectively. On the other hand, RSD 
values obtained for three different days (n=15) were better than 6.6% and 2.9% for peak 
areas and migration time, respectively, assuring an adequate repeatability of the 
analysis. 
 
In spite of these good results, the present method can sill be improved as can be 
deduced from the numerous impurities that are obtained from the FITC derivatization 
(see peaks marked with an asterisk in Figure 1) that can interfere in the determination of 
other amino acids not included in the standard mixture. However, given the good 
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figures of merit in terms of resolution, efficiency and sensitivity of this chiral-MEKC-
LIF procedure, this method was used to carry out the chiral amino acids profiling in 
CSF samples. 
 
Identification and relative quantitation of D/L-amino acids in CSF samples related 
to different AD stages 
 
Amino acids from CSF samples related to different AD stages were derivatized and 
analyzed by chiral-MEKC-LIF using the selected conditions described above. The 
investigated CSF samples were taken from control subjects (S1 pool, n=33 individuals), 
subjects showing a MCI who remained stable (S2 pool, n=26 individuals), subjects 
showing a MCI that progressed to AD (S3 pool, n=13 individuals) and subjects 
diagnosed with AD (S4 pool, n=27 individuals). In order to identify the different 
enantiomers, a co-injection procedure as shown in Figure 2 was applied allowing the 
accurate identification of 11 free L/D-amino acids in all the CSF samples. Namely, L-
Arg, L-Leu, L-Gln, GABA, L-Ser, D-Ser, L-Ala, Gly, L-Lys, L-Glu and L-Asp were 
identified in all the investigated CSF samples. As can be deduced from our results, the 
only D-amino acid found in CSF was D-Ser. Interestingly, D-Ser is thought to have an 
important function in the central nervous system (CNS) of mammals to modulate the N-
methyl-D-aspartate (NMDA) subtype of glutamate receptor [5,28,29]. Thus, the finding 
of D-Ser is in good agreement with the fact that only for this D-amino acid it has been 
possible to demonstrate its natural origin based on the activity of the enzyme serine 
racemase that catalyzes the direct racemization of L-Ser to D-Ser [5]. So far, there is not 
a clear explanation for other D-amino acids that have sometimes been found in 
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mammalians including CSF samples, suggesting that they can be derived from nutrition 
or in many biological samples from bacteria [5].  
 
As already mentioned, further studies are needed to clarify whether the alterations in D-
amino acids in AD CSF is a factor or a result. In this regard, a correct clinical diagnosis 
of AD early in the course of the disease is crucial to initiate symptomatic treatment, and 
will be even more important when disease-arresting drugs, such as beta-sheet breakers 
or gamma-secretase inhibitors, will reach the clinic. However, there is no clinical 
method to determine if a patient with MCI has incipient AD, i.e. will progress to AD 
with dementia, or have a benign form of MCI without progression [30]. Thus, there is a 
great clinical need for diagnostic biomarkers to identify incipient AD in MCI cases. 
With this idea in mind, our next step was to inject the CSF samples from the four 
different groups studied in this work, which included control subjects (S1), subjects 
showing MCI who remained stable (S2), subjects showing MCI that progressed to AD 
(S3) and subjects already diagnosed with AD (S4). 
 
The relative levels of the 11 amino acids found in the CSF samples from S1 to S4 
groups are given in Table 3, together with their standard deviation after triplicate 
analysis. Mean values were also compared and the results are included as superscripts. 
Some interesting differences among the CSF samples are observed in Table 3. Thus, 
using the statistical approach described in Data analysis (vide supra) the most 
significant variables (p<0.01) able to differentiate S1-S2 (non AD subjects) from S3-S4 
(AD subjects) were confirmed to be L-Glu, L-Arg, L-Asp, L-Lys and GABA. Thus, S3 
and S4 samples (i.e., AD subjects) showed significant (p<0.01) lower amounts of L-
Arg, L-Lys, L-Glu and L-Asp compared to the non-AD samples S1 and S2, observing in 
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the S4 sample the lowest amounts of L-Arg L-Lys and L-Glu. Similar results were 
mentioned by D'Aniello et al. [17] who observed that aspartic acid occurred at 
significantly lower concentrations in CSF from AD patients than in CSF from healthy 
individuals. Also, these results seem to be in good agreement with the excitatory role of 
some of these amino acids. Thus, as the major excitatory neurotransmitters in the 
mammalian CNS, Glu and Asp are present in more than half of all CNS synapses, 
which underscores their important involvement in e.g., learning, memory or movement 
[31,32]. Based on the observed decrease of these crucial functions in AD patients, it 
could be expected lower levels of L-Glu and L-Asp in the AD patients as corroborated 
by results in Table 3. 
 
Moreover, GABA was significantly higher (p<0.01) in AD subjects from S3 and S4 
compared to S1 and S2, with the highest amount of GABA also found in S4. Our results 
do not agree with those reported by Bergquist et al. [20] who analyzed CSF samples 
from patients with AD and other neurological diseases observing that GABA levels 
were reduced in the CSF of AD patients, while Gly levels in the AD patients were 
elevated. This disagreement can be explained considering that GABA and Gly are the 
main inhibitory neurotransmitters in the CNS [33]. In fact, as many as 10-40% of nerve 
terminals in the hippocampus and cerebral cortex may use GABA as a neurotransmitter 
to transmit “closure” signals [22,34]. Therefore, GABA and/or Gly can be expected to 
increase in AD patients considering their main activity as inhibitory neurotransmitters 
of the CNS. This finding is also supported by Lanctot et al [35] who hypothesized that 
the variable findings regarding GABA disruption in AD patients would reflect subtypes 
of this disease that could possibly be manifested clinically by differing behavioural 
symptoms.  
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No significant differences (p<0.01) were observed for the rest of amino acids including 
D-Ser. Interestingly, the result on D-Ser does not agree with those reported by Fisher et 
al. [25,26] who in the 90’s found using HPLC that free D-Ser in CSF from AD patients 
was significantly higher than in normal subjects. Since then, to our knowledge, the 
present work is the only published study on the level of D- and L-amino acids in CSF 
samples related to AD and it seems to rebut the accepted hypothesis of a higher level of 
D-Ser in Alzheimer CSF. Moreover, similar results were found by other authors in 1993 
[36] and 1995 [37] using HPLC they did not observe significant differences in the level 
of D-Ser in normal and Alzheimer human brain. In this regard, some authors have 
mentioned that CSF contamination with erythrocytes could also increase D-Ser 
concentration [38]. In our opinion, when combining the results from the above studies, 
there is no consistent D-Ser disruption in AD CSF samples. Thus, D-Ser should not be 
considered at this moment a reliable diagnostic marker for AD when analyzing CSF 
samples.  
 
Although a larger number of samples has to be analyzed in order to confirm the above 
findings, it is interesting to remark that significant difference in all the investigated 
samples was only observed for 5 compounds out of the 18 investigated. Thus, other two 
compounds differing more than statistically expected were Gly and L-Leu. However, 
the statistically significant difference for Gly and L-Leu is not systematically observed 
for all the groups as can be deduced from the results given in Table 3. 
 
To confirm the conclusions obtained from the statistical analysis discussed above, all 
the data as a whole were subjected to a forward stepwise discriminant analysis (FSDA). 
The data matrix has dimensionality 12·7 (seven chiral-MEKC-LIF peak areas chosen 
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from electropherograms of the four CSF groups, S1 to S4, run in triplicate), data 
analysis was carried out as described in the Experimental Section. In Figure 3, each 
point represents one particular chiral-MEKC-LIF electropherogram confirming the 
straightforward statistical analysis performed above. L-Glu, L-Arg, L-Asp, L-Lys and 
GABA were selected as the most important variables to differentiate the four groups of 
samples. Values of 4.0 and 3.9 were considered for F-statistic to enter and to remove 
variables, respectively. With these five amino acids it was possible to classify all 
samples correctly, as can be seen in Figure 3, the four groups S1, S2, S3 and S4 are 
nicely separated using this approach. The classification matrix of this analysis reveals 
L-Glu, L-Asp and L-Lys as crucial for the four groups sorting. The factor structure 
matrix associated to the FSDA highlight L-Glu and L-Arg as the amino acids which 
most contributes to AD and non-AD classification. Namely, S1 and S2 (non AD 
samples) can be clearly separated from S3 and S4 (AD samples) only by analyzing the 
levels of these two compounds. Interestingly, the decrease observed in L-Glu and L-Arg 
in AD CSF samples seems to be in good agreement with the much higher amount of 
GABA found in the same samples, since GABA is produced from L-Arg via their 
conversion to ornithine and L-Glu by the action of the enzyme arginase also found in 
the brain [39-41]. However, some other possible explanations of the decrease of L-Arg 
in AD CSF samples cannot be ruled out, including a major concentration or activity of 
enzymes using L-Arg as substrate as e.g., nitric oxide synthase or peptidylarginine 
deiminases [41,42].  
 
These results seem to demonstrate the good possibilities of chiral-MEKC-LIF analysis 
of CSF samples as a clinical diagnostic tool of AD even at the early stages of this 
disease. Moreover, as can be deduced from the good separation between groups S2 and 
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S3 it seems that chiral-MEKC-LIF analysis of CSF samples could be proposed as a 
clinical method to determine if a patient with MCI has incipient AD, i.e. will progress to 
AD with dementia (group S3), or have a benign form of MCI without progression 
(group S2). More samples have to be analyzed to corroborate this point. 
 
CONCLUDING REMARKS 
 
Differences in chiral amino acid levels are clearly observed among the sample pools 
from different patients examined in this study, indicating that AD related differences in 
CSF amino acid profiles can be examined effectively by chiral-MEKC-LIF. Some of the 
results shown in this work seem to rebut those shown in literature (e.g., not significant 
variation on D-Ser level was observed depending on the AD stage), while some of them 
agree with the results obtained by others (e.g., L-Asp occurs at significantly lower 
concentrations in Alzheimer CSF than normal CSF). Moreover, it is also preliminarily 
proposed that L-Glu, L-Arg, L-Asp, L-Lys and GABA could be used as biomarkers able 
to differentiate MCI patients who will progress to AD from those having a benign form 
of MCI without progression.  
 
From this work, it is concluded that enantioselective procedures can open new 
perspectives in the discovery of biomarkers related to different stages of AD. However, 
more CSF samples will have to be analyzed in order to use L- and D-amino acids 
profiles from chiral-MEKC-LIF to make specific conclusions about neurological 
disorders such as AD. Moreover, the effect of other conditions (e.g. diet) on the level of 
D-amino acids found in CSF should also be studied, since the endogenous origin of 
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some D-amino acids is already known (i.e., D-Ser), but it is not clear yet the origin of 
others D-amino acids found in CSF samples in other works. 
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FIGURE LEGENDS 
 
Figure 1. MEKC-LIF electropherograms of a standard mixture of 18 D/L amino 
acids (10 µg/mL D/L-Arg, D/L-Leu, D/L-Gln, GABA, D/L-Ser, D/L-Ala, D/L-Glu, 
5 µg/mL Gly, 50 µg/mL D/L-Lys and D/L-Asp). Peaks marked with an asterisk 
correspond to FITC peaks. Background electrolyte: 100 mM sodium tetraborate, 80 
mM SDS, 20 mM -CD at pH 10.0. FITC-derivatized amino acids injected for 3 s at 
0.5 psi; bare fused-silica capillary with 57 cm total length, 50 cm detection length, 
and 50 µm i.d.; running voltage, 20 kV; LIF detection, Ar+ laser at 488 nm 
(excitation wavelength) and 520 nm (emission wavelength). 
 
Figure 2. MEKC-LIF analysis of CSF sample S2 (solid trace A) and CSF sample 
spiked with D/L-Leu, D/L-Gln, GABA, D/L-Ser, D/L-Ala and Gly (dotted trace B). 
Peaks marked with * correspond to FITC-related peaks and those marked with ** 
correspond to unidentified peaks from CSF sample. All the analytical conditions as 
in Figure 1. 
 
Figure 3. Scatter plot of the chiral-MEKC-LIF electropherograms (each point 
represents one electropherogram) in the plane defined by the two canonical 
variables (Root 1 and Root 2) obtained from FSDA selected variables: L-Glu, L-
Arg, L-Asp, L-Lys and GABA. These amino acids classify successfully (100% of 
classification for all groups) the four pooled samples: S1 (control CSF), S2 (stable 
MCI), S3 (MCI with progression to AD) and S4 (AD). Ellipses surrounding the four 
groups are drawn for a better visualization. See text for more details. 
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Table 1. Figures of merit of the chiral-MEKC-LIF method developed in this work.  
 
 
Amino acid LOD (nM)
a) 
Efficiency
b) 
Resolution
c)
 
D-Arg 1.6 703000 
2.6 
L-Arg 1.6 686000 
D-Leu 0.9 492000 
7.0 
L-Leu 0.7 467000 
D-Gln 0.9 433000 
4.4 
L-Gln 1.0 440000 
GABA 1.1 419000 - 
D-Ser 1.9 441000 
3.5 
L-Ser 1.9 444000 
D-Ala 2.0 363000 
4.0 
L-Ala 2.3 417000 
Gly 0.8 384000 - 
D-Glu 3.4 299000 
9.5 
L-Glu 4.4 282000 
D-Lys 11.7 292000 
2.7 
L-Lys 12.3 297000 
D-Asp 15.4 272000 
7.3 
L-Asp 16.5 242000 
 
a)
 Limit of detection (LOD) calculated for a signal/noise ratio of 3. 
b)
 Efficiency (N) calculated as number of theoretical plates per meter of column. 
c)
 Resolution (R) between two peaks (namely, 1 and 2) was calculated using the next 
formula: R= (t2 – t1)/(w2 –w1), where t1 and t2 are the analysis time of enantiomers 1 and 
2, respectively, and w1 and w2 are the widths at the base of enantiomers 1 and 2, 
respectively. 
 24 
Table 2. Time analysis and corrected peak area reproducibility (determined as relative 
standard deviation, %RSD) of the chiral-MEKC-LIF method for the same day (n=5) and 
three different days (n=15).  
 
 
 
 amino acid 
%RSD (intraday)  %RSD (three days)  
tmig 
Corrected 
peak area 
tmig 
Corrected 
peak area 
D-Arg 0.3 3.8 2.0 5.0 
L-Arg 0.3 4.2 2.0 5.0 
D-Gln 0.3 3.0 2.1 5.2 
L-Gln 0.5 3.9 2.1 5.8 
D-Ser 0.5 2.8 2.3 5.9 
L-Ser 0.4 4.5 2.4 6.1 
D-Asp 0.5 4.8 2.7 6.3 
L-Asp 0.3 5.3 2.9 6.6 
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Table 3. Mean values ( standard deviation) of relative levels of L- and D-amino acids 
found in the four different CSF pools analyzed. CSF samples were taken from control 
subjects (S1 pool), subjects showing a mild cognitive impairment (MCI) who remained 
stable (S2 pool), subjects showing a MCI that progressed to AD (S3 pool) and subjects 
diagnosed with AD (S4 pool). 
 
 
 
Amino 
acid 
CSF-S1 pool CSF-S2 pool CSF-S3 pool CSF-S4 pool 
Rel. level
1) 
(±SD)
2)
 Rel. level (±SD) Rel. level (±SD) Rel. level (±SD) 
D-Arg ND
3) 
ND ND ND 
L-Arg 1423
b
 ± 113 1243
b
 ± 63 868
a
 ± 44 802
a
 ± 16 
D-Leu ND ND ND ND 
L-Leu 839
a
 ± 51 1107
b
 ± 108 1253
b
 ± 40 1295
b
 ± 40 
D-Gln ND ND ND ND 
L-Gln 9174
a
 ± 449 9373
a
 ± 101 8933
a 
± 166 9161
a
 ± 120 
GABA 1137
a
 ± 108 1370
ab
 ± 22 1611
bc
 ± 22 1805
c
 ± 162 
D-Ser 274
a
 ± 17 266
a
 ± 23 236
a
 ± 21 239
a
 ± 13 
L-Ser 779
a
 ± 30 769
a
 ± 22 731
a
 ± 36 715
a
 ± 25 
D-Ala ND ND ND ND 
L-Ala 1295
a
 ± 134 1302
a 
± 57 1258
a
 ± 114 1189
a
 ± 47 
Gly 588
b
 ± 51 328
a
 ± 12 332
a 
± 15 298
a
 ± 29 
D-Lys ND ND ND ND 
L-Lys 173
c
 ± 5 160
bc
 ± 11 139
b
 ± 10 104
a
 ± 7 
D-Glu ND ND ND ND 
L-Glu 87
b
 ± 4 84
b
 ± 2 43
a
 ± 6 39
a
 ± 2 
D-Asp ND ND ND ND 
L-Asp 29
b
 ± 2 30
b
 ± 2 17
a
 ± 1 19
a
 ± 1 
 
1) 
Relative level given in arbitrary units and calculated as corrected peak area (peak 
area/migration time). 
2) 
Standard deviation (n=3). 
3) 
Not detected. 
a-d
: rows without a common letter are significantly different (p<0.01) 
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Figure 2 
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Figure 3  
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